ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Factors influencing patient-reported symptom outcomes in women with metastatic breast cancer.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Symptom Burden and Treatment Satisfaction Among Patients with Cancer in a Day Care Unit.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUtilization of targeted agents and immunotherapy led to improved survival in women with metastatic breast cancer (MBC). However, a knowledge gap remains about the side effects and symptom burden associated with these therapies that are not fully described for people living with MBC. We examined patient-reported symptom severity, interference, and symptom burden related to MBC cancer treatments and identified correlated sociodemographic and clinical factors.
methodsThis is a cross-sectional study. Women with MBC on systemic cancer treatment recruited from oncology clinics and advocacy organizations completed a survey from February to September 2024. We used the MD Anderson Symptom Inventory (MDASI) Immunotherapy module to describe symptom severity and interference of 20 symptoms and symptom burden. We conducted descriptive statistics and stepwise multiple linear regression to identify sociodemographic and clinical factors correlated with symptom severity, interference, and symptom burden.
resultsIn the sample of 209 participants, the mean age was 50.11 years (SD = 14.12); 76.6% were White. Most were HR+/HER2- subtype, with an average time of 4.35 years since MBC diagnosis. Fatigue, sleep disturbance, forgetfulness, drowsiness, and sadness were the most prevalent symptoms. Participants identified as non-White, have completed more lines of treatments reported higher symptom severity, interference, and total symptom burden. However, having dependent children (β = 0.32, 95% CI [0.04, 0.60], P = 0.027) was associated with more severe symptom interference.
conclusionThe type and number of treatments, being non-White and caring for dependent children, were associated with a higher symptom burden. Symptom management interventions should be tailored for a specific MBC subgroup and to improve overall well-being for the MBC population.
Indexed as
Identifiers
41731206What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.